PDCD1 and non-small cell lung carcinoma: Additionally, Tomita et al. evaluated the effects of Clostridium butyricum (CBT), a commonly used probiotic in Japan, on anti-PD-1/PD-L1 therapeutic efficacy in 118 patients with advanced NSCLC.